Enwei Pharmaceutical Co

Enwei Pharmaceutical Co FCF Yield

The Free Cash Flow Yield of Enwei Pharmaceutical Co (301331.SZ) as of Oct 21, 2026 is 6.53 %. In the previous year, Free Cash Flow Yield was 3.52 % — a change of 85.49% (higher).

FCF Yield

6.53 %

YoY

85.49%

Last updated:

Free Cash Flow Yield of Enwei Pharmaceutical Co is 2025 6.53 % . Free Cash Flow Yield of Enwei Pharmaceutical Co was 2024 3.52 % . It decreases by 85.49% higher compared to the previous year.

The Enwei Pharmaceutical Co FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2019
12.09 CNY
Jan 1, 2020
5.81 CNY
Jan 1, 2021
6.06 CNY
Jan 1, 2022
4.76 CNY
Jan 1, 2023
-6.14 CNY
Jan 1, 2024
3.52 CNY
Jan 1, 2025
6.53 CNY
The Enwei Pharmaceutical Co FCF Yield history
YEARFCF YieldYoY
6.53 %+85.49%
3.52 %-157.33%
-6.14 %-228.98%
4.76 %-21.41%
6.06 %+4.24%
5.81 %-51.90%
12.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enwei Pharmaceutical Co Stock analysis

What does Enwei Pharmaceutical Co do? Enwei Pharmaceutical Co., Ltd. generates revenue through the research, development, production, and sales of proprietary Chinese and chemical medicines. The company's main products include Jieeryin lotion, Jieeryin ointment, Jieeryin effervescent tablets, Shanmai Jianpi oral liquid, Qingjing capsules, and Danxiong Tongmai granules, which are primarily sold via direct sales and e-commerce channels. Its focus on gynecological products, pediatric medicines, and respiratory medicines targets domestic consumers seeking specialized healthcare solutions. The firm's domestic market strategy emphasizes direct customer engagement and online sales to reach its target segments. The company's product portfolio is tailored to specific health needs, with Jieeryin products addressing gynecological concerns, Shanmai Jianpi oral liquid supporting digestive health, Qingjing capsules for gynecological treatments, and Danxiong Tongmai granules targeting cardiovascular health. These offerings are distributed through direct sales teams and e-commerce platforms, aligning with the domestic market's preference for accessible healthcare products. Enwei's domestic focus ensures that its products meet local regulatory standards and consumer demands. Enwei Pharmaceutical's revenue streams are driven by the consistent demand for its specialized medicine categories, particularly in gynecology, pediatrics, and respiratory care. The firm's domestic market presence allows it to build strong relationships with healthcare providers and end-users, facilitating repeat purchases and brand loyalty. By concentrating on these key therapeutic areas, Enwei effectively serves its core customer segments without expanding into international markets. Enwei Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enwei Pharmaceutical Co stock

Free Cash Flow Yield of Enwei Pharmaceutical Co is 6.53 % in 2025.

Free Cash Flow Yield of Enwei Pharmaceutical Co changed from 3.52 % to 6.53 %, representing a 85.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Enwei Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Enwei Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Enwei Pharmaceutical Co

All Key Metrics — Enwei Pharmaceutical Co